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Sphingolipids (SLs) are a diverse family of natural metabo-
lites composed of a fatty acyl chain attached to a polar head-
group derived from L-serine that together form the sphingoid 
base core (1). Amphipathic in nature, SLs are important 
structural components of eukaryotic membranes that can as-
sociate with each other and with other membrane compo-
nents (such as cholesterol and proteins) in regions called 
lipid rafts (2). As well as this structural role, SLs are now rec-
ognized as fundamental signaling molecules with a vast array 
of functions within cells. A “sphingodynamics” model has 
been proposed to encompass both intra- and extracellular 
signaling by all bioactive SL intermediates and their metabo-
lites (3). Sphingosine-1-phosphate (S1P) is one such SL that 
regulates a plethora of physiological processes in humans by 
activating five different G protein-coupled S1P receptors 
(named S1PRs 1–5) (4). Perturbing the cellular levels of S1P 
can have serious consequences and has been linked to dis-
eases such as cancer, diabetes, atherosclerosis, osteoporosis, 
and neurodegeneration (5, 6). The balance between S1P 
and ceramide, another signaling molecule that often has op-
posing cellular effects to S1P, is governed by a “sphingolipid 
rheostat” (6, 7). Remarkably, the pyridoxal 5′-phosphate 
(PLP)-dependent enzyme, S1P lyase (S1PL), is the only 
known enzyme capable of irreversibly removing sphingoid 
bases from the SL pool. S1PL catalyzes the retro-aldol-like 
Abstract Sphingolipids (SLs) are ubiquitous elements in 
eukaryotic membranes and are also found in some bacterial 
and viral species. As well as playing an integral structural 
role, SLs also act as potent signaling molecules involved in 
numerous cellular pathways and have been linked to many 
human diseases. A central SL signaling molecule is sphingo-
sine-1-phosphate (S1P), whose breakdown is catalyzed by 
S1P lyase (S1PL), a pyridoxal 5′-phosphate (PLP)-dependent 
enzyme that catalyzes the cleavage of S1P to (2E)-hexadecenal 
(2E-HEX) and phosphoethanolamine. Here, we show that the 
pathogenic bacterium, Burkholderia pseudomallei K96243, 
encodes two homologous proteins (S1PL2021 and S1PL2025) 
that display moderate sequence identity to known eukaryotic 
and prokaryotic S1PLs. Using an established MS-based meth-
odology, we show that recombinant S1PL2021 is catalytically 
active. We also used recombinant human fatty aldehyde de-
hydrogenase to develop a spectrophotometric enzyme-
coupled assay to detect 2E-HEX formation and measure the 
kinetic constants of the two B. pseudomallei S1PL isoforms. 
Furthermore, we determined the X-ray crystal structure of 
the PLP-bound form of S1PL2021 at 2.1 Å resolution re-
vealing that the enzyme displays a conserved structural 
fold and active site architecture comparable with known 
S1PLs.  The combined data suggest that B. pseudomallei 
has the potential to degrade host SLs in a S1PL-dependent 
manner.—McLean, C., J. Marles-Wright, R. Custodio, J. 
Lowther, A. J. Kennedy, J. Pollock, D. J. Clarke, A. R. Brown, 
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metabolism in Burkholderia, so we began by investigating to 
determine whether this species contains any of the known SL 
metabolic enzymes, and the recent work on the L. pneumoph-
ila focused our attention on S1PL. We searched the B. pseudo-
mallei K96243 genome (20, 21) and, surprisingly, found two 
open reading frames (ORFs), BPSS2021 and BPSS2025, 
whose gene products (S1PL2021 and S1PL2025, respec-
tively) displayed high sequence identity to each other and 
moderate sequence conservation to confirmed S1PLs from 
bacteria, yeast, and humans. We felt that this unusual gene 
duplication merited further study; thus, we set out to charac-
terize the biochemical properties of these putative B. pseudo-
mallei S1PLs as a prelude to investigating their role in the 
host-pathogen interaction.
A number of assays that monitor S1PL activity have been 
reported in the literature. Many use either radioactive 
(e.g., 3H or 14C) or fluorescently-labeled (e.g., BODIPY) S1P 
analogs that generate labeled 2E-HEX aldehyde that can 
be detected by scintillation counting or fluorescent meth-
ods, respectively (22–25). Other assays rely on the chemical 
derivatization of the HEX aldehyde product using chemi-
cal reagents, then applying MS to quantify the amount of 
material (LC-ESI-MS/MS, GC-MS, HPLC-ESI-QTOF, etc.) 
(26–28). Each approach has its merits with respect to sensi-
tivity, limit of detection, and the ability to work with puri-
fied enzyme, cell-free extracts, or in whole cells. However, 
the drawbacks include the use of radioactive or nonnatural 
substrates, limited throughput, and the requirement for 
the extraction of the S1PL reaction products. First, using 
an established MS-based methodology, we validated that the 
recombinant S1PL2021 displayed S1PL activity (26). Then, 
to further characterize the two closely-related B. pseudomallei 
S1PLs, we generated a coupled spectrophotometric method 
for the convenient measurement of S1PL activity. This as-
say couples the activity of these new S1PLs with a recombi-
nant form of human FALDH that is part of the 2E-HEX 
catabolic pathway. In this way, we were able to measure the 
production of 2E-HEX via the reduction of the FALDH 
NAD+ cofactor to NADH. Furthermore, we determined the 
X-ray crystal structure of the S1PL2021 isoform at 2.1 Å and 
revealed that it has features in common with bacterial, 
yeast, and human S1PL homologs. As well as reporting a 
convenient assay for S1PL activity, this study lays the foun-
dation for future studies of the role of these novel S1PLs in 
the growth and pathogenicity of Burkholderia.
MATERIALS AND METHODS
Materials
Plasmids and E. coli competent cells for cloning were purchased 
from Novagen and New England BioLabs. The E. coli BL21 (DE3) 
competent cells used for protein expression were from Agilent. 
All chromatography columns were from GE Healthcare. Hotstart 
Pfu polymerase was from Agilent. Restriction enzymes were from 
New England BioLabs. Oligonucleotide primers were sourced 
from Sigma. Substrate S1P (CAS number: 26993-30-6) was from 
Cayman Chemical Co. 2E-HEX was synthesized in house using a 
published method (29). All other buffers and reagents were 
sourced from Sigma.
breakdown of S1P to (2E)-hexadecenaldehyde (2E-HEX) 
and phosphoethanolamine (PE) (Fig. 1). In eukaryotes, 
the 2E-HEX is oxidized by fatty aldehyde dehydrogenase 
(FALDH; also known as ALDH3A2) to the hexadecenoic 
acid, which links the SL and glycerol phospholipid metabolic 
pathways (8). Saba, Hannun, and colleagues were the first to 
clone a S1PL gene (also known as dpl1 and BST1) from Sac-
charomyces cerevisiae in 1997 (9) and, subsequently, the human 
homolog was characterized in 2000 (10). Because S1P plays a 
role in numerous diseases, enzymes in the S1P biosynthetic 
and degradative pathways are now seen as attractive drug tar-
gets (3). To that end, Novartis recently published results of a 
medicinal chemistry study that identified potent and specific 
inhibitors of human S1PL (11).
Nearly all Gram-negative bacteria such as Escherichia coli, 
Legionella pneumophila, and Burkholderia pseudomallei contain 
lipopolysaccharides as the major lipid component in their 
cell membranes. In contrast, the number of bacteria that pro-
duce SLs, examples being Sphingomonas spp (12) and Myxo-
bacterium spp (13), is relatively small. However, it is interesting 
to note that many of the bacteria that are part of the human 
microbiome, such as Bacteroides fragilis and Porphyromonas gin-
givalis, also produce SLs (14–16). This raises the interesting 
question of what is the function of bacterial SLs? Moreover, if 
such species contain an S1PL enzyme, what role does it play 
in bacterial metabolism in general and in the host-microbe 
interaction in particular? Recent studies have begun to ad-
dress these questions. A bacterial S1PL homolog (LegS2) was 
identified in the intracellular human pathogen, L. pneumoph-
ila (17, 18), and its role as a virulence factor in the patho-
genic mechanism of this organism was explored. B. 
pseudomallei is an intracellular Gram-negative pathogen that 
causes serious disease in humans and animals and, as such, is 
classified by the Centre for Disease Control as a category B 
biothreat agent. B. pseudomallei infection results in melioido-
sis, a febrile and potentially fatal disease that has a high mor-
tality rate (19). To date, there have been no studies on SL 
Fig. 1. Metabolism of S1P. S1PL catalyzes the degradation of S1P 
to 2E-HEX and PE. The 2E-HEX product is a substrate for the 
NAD+-dependent enzyme, FALDH, which oxidizes 2E-HEX to the 
fatty acid with the concomitant reduction of the NAD+ cofactor.
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S1PL2025 forward, 5′ CCATGGATCTGGAGGAAGGCATCAG 3′ 
and S1PL2025 reverse, 5′ CTCGAGAAGCGGGCAATCCGTGAAC 
3′ to give an expressed protein sequence that aligned with the 
shorter S1PL2021 form described above. The purified PCR prod-
uct was cloned into the pGEM T-Easy vector by TA ligation and 
positive clones were isolated and sequenced to confirm the iden-
tity of the gene. A positive pGEM/S1PL2025 clone was digested 
with NcoI and XhoI, and the isolated S1PL gene ligated into pET-
28a to give a C-terminally six His-tag protein of 480 amino acids. 
Expression of the gene and purification of the protein product 
were essentially identical to that for S1PL2021.
Cloning and expression of full-length and truncated 
FALDH
The full-length FALDH gene sequence (coding isoform 2) was 
purchased as a cDNA clone from Imagenes in a pOTB7 vector 
(UniProt code, P51648). Full-length FALDH (isoforms 1 and 2) is 
predicted to contain a C-terminal membrane-bound helix, thus 
using this as a template. Full-length and truncated versions for the 
FALDH isoform 1 (the major natural form) coding sequences 
were amplified by PCR using forward and reverse primers with 
NdeI/NcoI and XhoI restriction enzyme sites: FALDH forward, 5′ 
CATATGGAGCTCGAAGTCCGGCGGGTCCGACAGG; FALDH 
reverse, 5′ CTCGAG(TCA)TAATATTCCGCCTTGACAAGCA-
CAGCGGCTACAAT; Truncated FALDH reverse, 5′ CTCGAGA-
TCCACCTTTGACTGGCTGTTGGG. The purified PCR products 
were cloned into pGEM, sequence verified, and then cloned into 
pET-28a as described for the S1PL constructs as an N-terminally 
hexa-his-tagged protein. pET-28a plasmids containing both ver-
sions of FALDH (full-length and C-terminal truncation) were used 
to transform E. coli BL21 (DE3) competent cells and selection was 
carried out on LB/Kan30 plates. Single colonies were used to in-
oculate 2 × 250 ml of LB/Kan30 broth and overnight cultures were 
grown at 37°C with shaking at 250 rpm. The overnight cultures 
were used to inoculate 4.5 l of fresh LB/Kan30 broth and grown to 
an A600 of 0.6–0.8. Protein expression was induced by addition of 
IPTG to a final concentration of 0.1 mM and growth was contin-
ued for 5 h at 22°C. Cells were harvested by centrifugation (Sorvall 
RC5-B centrifuge) at 5,000 rpm for 15 min at 4°C.
General procedure for the purification of six his-tagged 
enzymes (S1PL2021, S1PL2025, and FALDH)
All purification steps were carried out at 4°C. All buffers con-
tained 20 mM HEPES (pH 7.5), 400 mM NaCl, and 10% glycerol. 
PLP (100 M) was included in the buffer for S1PL isolation. Bind-
ing buffers also contained 10 mM imidazole and one EDTA-free 
protease inhibitor tablet (Roche). Wash buffer contained 30 mM 
imidazole with elution buffer containing 300 mM imidazole. Cell 
pellets (4 g) were resuspended in Ni-NTA binding buffer 10:1 
(v/w). Cells were lysed by sonication (Soniprep 150) for 15 cycles 
(30s on, 30 s off) on ice. In the case of full-length FALDH, 
0.1% N-lauroylsarcosine was added to aid solubilization of the re-
combinant protein. The lysed cell suspension was centrifuged at 
20,000 rpm for 30 min. The cell-free extract was filtered (0.45 m 
syringe filter) before addition of 2 ml Ni-NTA resin (Qiagen) pre-
equilibrated with binding buffer. Binding was carried out by ro-
tating the suspension at 4°C for 1 h. The resin was collected by 
gravity flow in a fritted plastic disposable column, washed with 
30 ml wash buffer, and the bound protein eluted with 5 ml elution 
buffer. Fractions were analyzed by SDS-PAGE and the 300 mM 
imidazole eluate loaded onto a pre-equilibrated HiPrep™ 16/600 
Superdex™ S-200 size exclusion column. Recombinant protein 
was eluted at a flow rate of 1 ml/min in buffer. The molecular 
weights of S1PL or FALDH were calculated from a calibration curve 
using known molecular mass standards (GE Healthcare). The pu-
rity of the recombinant proteins was analyzed by SDS-PAGE. The 
Sequence alignment and prediction tools
Sequence data searches were performed using the BLAST suite 
of programs. Multiple sequence alignments were carried out us-
ing the Clustal series of programs (30) with structural modeling 
performed using the Phyre2 server (31). To find S1PL homologs 
in the curated B. pseudomallei genome (www.burkholderia.com), 
the S1PL sequence from Symbiobacterium thermophilim [UniProt 
code, Q67PY4; Protein Data Bank (PDB) code, 3MAU] was used 
to carry out a standard BLAST analysis. This recovered two hit 
genes, annotated as BPSS2021 (UniProt code, Q63IP8) and 
BPSS2025 (Uniprot code, Q63IP4) with moderate sequence iden-
tities to the template (43% and 44%, respectively). The encoded 
proteins, referred to as S1PL2021 and S1PL2025, share 86% se-
quence identity.
Cloning and expression of BPSS2021 (S1PL2021)
Sequence analysis suggested that the BPSS2021 gene could 
be expressed from two start codons to give two ORFs. Therefore, 
PCR forward and reverse primers were designed based on the lon-
gest ORF (S1PL2021 N-EXT) using the following primers: 
S1PL2021 forward, 5′ CCATGGTGCGTTCGATCGC 3′; S1PL2021 
reverse, 5′ CTCGAGCGGACAGTCGGTAAACAG 3′. These prim-
ers incorporated NcoI and XhoI restriction sites giving a C-terminal 
six-histidine-tagged fusion. A positive pGEM/S1PL2021 N-EXT 
clone was digested and the isolated S1PL gene ligated into pET-
28a. This gave a pET-28a/S1PL2021 N-EXT construct that ex-
pressed a protein of 500 amino acids. To clone the shorter ORF 
(S1PL2021), a forward primer was designed to initiate expression 
from an ATG start codon 60 base pairs downstream of the anno-
tated start codon: S1PL2021 TRUNC forward, 5′ CCATGGATCTC-
GAAGAAGG 3′. This PCR product was also cloned into pET-28a 
via a pGEM intermediate to give a pET-28a/S1PL2021 plasmid 
encoding a protein of 480 amino acids. Plasmids pET-28a/
S1PL2021 N-EXT and pET-28a/S1PL2021 were used to transform 
E. coli BL21 (DE3) competent cells and selection was carried out 
on agar plates containing kanamycin (30 g/ml; LB/Kan30). Sin-
gle colonies were used to inoculate 2 × 250 ml of LB/Kan30 broth 
and overnight cultures were grown at 37°C with shaking at 
250 rpm. The overnight cultures were used to inoculate 4 l of 
fresh LB/Kan30 broth and grown to an A600 of 0.6–0.8. Protein 
expression was induced by addition of IPTG to a final concentra-
tion of 0.1 mM and growth was continued for 5 h at 30°C. Cells 
were harvested by centrifugation (Sorvall RC5-B centrifuge) at 
11,385 g for 15 min at 4°C.
Cloning and expression of the S1PL2021 K271A mutant
S1PL2021C mutants were prepared using the method of Liu 
and Naismith (32) with primers that were designed to intro-
duce the relevant mutations: K271A forward, 5′ CGATACG-
CACGCGTTCGGCTACGGCCCGAAGGGC 3′; K271A reverse, 
5′CGCCCTTCGGGCCGTAGCCGAACGCGTGCGTATCG 3′. PCR 
reactions were set up using Hotstart Pfu polymerase with com-
pleted reactions digested with Dpn1 enzyme to degrade template 
DNA. The post digestion mixture was transformed into high clon-
ing efficiency cells (C2987; New England BioLabs) and spread on 
LB/Kan30 plates. Colonies were picked into LB/Kan30 and grown 
overnight with plasmid DNA extracted from cells using a Qiaprep 
miniprep kit (Qiagen). Sequencing was performed to ensure that 
mutagenesis had occurred. Expression of the S1PL2021 mutants 
mirrored that of the wild-type with the exception that induction 
temperature was reduced to 28°C.
Cloning and expression of BPSS2025 (S1PL2025)
The coding sequence for the BPSS2025 gene was amplified 
from B. pseudomallei K96243 chromosomal DNA using primers 
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20 mM HEPES (pH 7.5), 400 mM NaCl, and 0.1 mM PLP (final 
well volume 150 l). This time, substrate S1P (0–175 M) was 
prepared in 1% Triton X-100 and added to separate reaction 
aliquots in triplicate. Reactions were monitored at 340 nm for 
30 min at 37°C. Kinetic data were fit using GraphPad as described 
previously.
X-ray crystallography
S1PL2021, at 6 mg/ml, was crystallized by hanging-drop vapor 
diffusion at 18°C. Crystallization experiments were set up in 
96-well MRC plates with commercially available screens from 
Molecular Dimensions Limited with 100 nl drops of protein and 
100 nl well solution and equilibrated against 70 l of well solu-
tion. Crystals grew in a well solution of 20% (v/v) polypropylene 
glycol 400 and 10% (v/v) 1-propanol (Molecular Dimensions 
MIDAS screen). Crystals were cryoprotected with mineral oil and 
then flash-cooled by immersion in liquid nitrogen. Datasets were 
collected on beamline I03 at the Diamond Light Source (Didcot, 
UK) at 100 K using a Pilatus 6M detector. Diffraction data were 
integrated and scaled using XDS (33) and symmetry-related re-
flections were merged with Aimless (34). The resolution cut off 
used for structure determination and refinement was determined 
based on the CC1/2 criterion proposed by Karplus and Died-
erichs (35). The structure of S1PL2021 was determined by mo-
lecular replacement using a model based on PDB code 3MAD, 
modified to match the target sequence using Chainsaw (36). A 
single solution comprising two molecules in the asymmetric unit 
was found using Phaser (37). The initial model was rebuilt using 
Phenix.autobuild (38) followed by cycles of refinement with Phe-
nix.refine (39) in the Phenix program suite (40) and manual re-
building in Coot (41) The final model was refined with isotropic 
B-factors and the model was validated using MolProbity (42) 
Structural superimpositions were calculated using Coot. Crystal-
lographic figures were generated with PyMOL (43)
RESULTS
Identification of putative Burkholderia S1PLs by BLASTp 
search
BLASTp hits for novel bacterial S1PLs were identified in 
the genomes of various species of Burkholderia by using the 
507 amino acid sequence of the confirmed bacterial S1PL 
from S. thermophilum, StS1PL (UniProt code, Q67PY4), as 
the query sequence (20, 44). Several putative S1PLs with 
>40% sequence identity were identified in the known hu-
man pathogen, B. pseudomallei, and in B. thailandensis, a 
nonpathogenic model organism (45). Strikingly, all repre-
sentatives of these species each encode two putative S1PLs, 
with the two genes located in close proximity within each 
species. This is exemplified by B. pseudomallei strain K96243, 
which contains two genes in close proximity with locus IDs 
of BPSS2021 (S1PL2021) and BPSS2025 (S1PL2025) that 
display 86.3% amino acid sequence identity between them 
and 43.9% and 43.1% identity, respectively, to the con-
firmed StS1PL (supplemental Figs. S1, S2). These two pre-
dicted S1PLs also contained the conserved residues 
involved in binding the PLP cofactor (44).
To characterize the recombinant forms of these putative 
S1PLs, we began by expressing S1PL2021 in E. coli, but the 
ORF displayed two potential start codons. The sequence 
identity between S1PL2021 with StS1PL was low at the 
fractions were pooled and protein concentration was calculated 
by A280 using the relevant extinction coefficients as determined 
using the Scripps Protein Calculator.
S1PL UV-visible spectroscopy
All UV-visible (UV-vis) spectra were recorded on a Cary 50 spec-
trophotometer (Varian) and analyzed using Cary WinUV software 
(Varian). S1PL enzymes (15–20 M) were maintained in holo-
form by dialyzing against buffer containing 20 mM HEPES (pH 
7.5), 400 mM NaCl, 10% glycerol, and 100 M PLP. Prior to 
spectroscopic measurements, excess PLP was removed using a 
PD-10 desalting column (GE Healthcare). A stock solution of S1P 
(1 mg/ml) was prepared in 1% Triton X-100 and sonicated. A 
stock solution of PE (100 mM) was prepared in water. S1P and PE 
were added to the enzymes and scans recorded between 300 and 
500 nm at appropriate time intervals.
Assay of S1PL activity by LC-MS
The activity of S1PL was determined by detecting the forma-
tion of the 2E-HEX semicarbazone (2E-HEX SC) product by LC-
MS using the method of Berdyshev et al. (26). Briefly, an enzyme 
stock solution was prepared by dialyzing 10 M S1PL in 20 mM 
HEPES (pH 7.5), 400 mM NaCl, and 100 M PLP. A 2.6 mM S1P 
stock was prepared with additional sonication. Using these stocks, 
an enzyme assay was prepared to a final volume of 500 l contain-
ing 6 M S1PL and 0.26 mM S1P substrate in a reaction buffer 
containing 20 mM HEPES, 400 mM NaCl, and 0.1 mM PLP. Con-
trol assays were prepared accordingly and all samples were incu-
bated for 20 min at 37°C with methanol then added to stop the 
reaction. The 2E-HEX was extracted and the semicarbazone 
derivative produced by heating reaction aliquots with 0.2 ml of 
5 mM semicarbazide hydrochloride in methanol containing 5% 
formic acid at 40°C for 2 h. The semicarbazones were analyzed by 
MS with samples injected via an Agilent 1200 HPLC with interfaced 
autosampler (Agilent Technologies). Analysis was in ESI-positive 
mode on a micro-TOF2 (Bruker Daltonics) using a standard ESI 
source. Ion source conditions were as follows: the ESI voltage was 
held at 4.5 kV at a temperature of 200°C with a hexapole RF of 
70 V peak to peak and skimmer 2 potential of 20 V.
Assay of FALDH activity using UV-vis spectroscopy
The soluble version of FALDH, lacking its C terminus, was as-
sayed to determine its suitability as a coupling enzyme with S1PL. 
This was done by monitoring the formation of NADH in the pres-
ence of a synthetic 2E-HEX substrate. Reaction aliquots were pre-
pared to a final volume of 500 l containing 1 mM NAD+, 500 nM 
FALDH in a reaction buffer containing 20 mM HEPES (pH 7.5) 
and 400 mM NaCl. Reactions were monitored by UV-vis at 340 nm 
for 30 min at 37°C. Subsequent assays were performed in a Syn-
ergy HT plate reader and the data plotted using GraphPad (non-
linear regression analysis) to gain kinetic data for FALDH. The 
reaction was linear over 5 min and the lower limit of detection 
was 4 M 2E-HEX.
S1PL:FALDH coupled-enzyme assay
S1PL enzyme assays were prepared to a final volume of 500 l 
containing 6 M S1PL, 1 mM NAD+, 500 nM FALDH in a reaction 
buffer containing 20 mM HEPES (pH 7.5), 400 mM NaCl, and 0.1 
mM PLP. The reaction was initiated by the addition of S1P from 
the stock solution to give a final concentration of 400 M. Control 
samples lacking enzyme or substrate were also prepared. Reac-
tions were monitored by UV-vis at 340 nm for 30 min at 37°C on a 
spectrophotometer. For kinetic data, the assays were then trans-
ferred to a Synergy HT plate reader and these contained 6 M 
S1PL, 1 mM NAD+, 500 nM FALDH in a reaction buffer containing 
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Addition of this substrate led to similar changes in the PLP 
region of the UV-vis spectrum that were observed for S1P, 
although this took significantly longer (4 h).
Confirmation that S1PL2021 is an S1PL
To determine whether the B. pseudomallei S1PL2021 and 
S1PL2025 displayed S1PL activity, we used an established 
MS-based method developed by Berdyshev et al. (26) that 
has been used to detect S1PL activity in mammalian liver 
microsomes. This method relies on extracting the 2E-HEX 
aldehyde product of the S1PL reaction and forming a 
stable semicarbazone derivative (2E-HEX SC, [M+H]+ 
C17H34N3O
+, predicted m/z 296.3 Da, observed m/z 296.3 
Da) using semicarbazide hydrochloride (Fig. 3A). Recom-
binant S1PL2021 was incubated with 260 M S1P and ali-
quots taken for semicarbazone derivitization. Additional 
positive and negative controls were prepared and treated 
in an identical manner and the results analyzed using ESI-
MS (Fig. 3B-E). The positive control used previously syn-
thesized 2E-HEX and gave a single peak at m/z 296.3 Da 
matching the expected semicarbazone derivative (Fig. 3B). 
This peak was absent in the no enzyme control with the S1P 
substrate ([M+H]+, predicted C18H39NO5P
+ m/z 380.2 Da, 
observed m/z 380.4 Da; Fig. 3C). The reaction catalyzed by 
S1PL2021 resulted in a signal with m/z 296.3 Da, indicating 
the production of the 2E-HEX SC species and confirming 
that S1PL2021 displayed S1PL activity (Fig. 3D). In con-
trast, the no substrate control lacked both of the above 
peaks (Fig. 3E).
FALDH coupled assay suitability/optimization
The ESI-MS method confirmed that S1PL2021 displays 
S1PL activity; therefore, we went on to develop a conve-
nient continuous spectroscopic assay in order to perform 
steady-state kinetic analysis of S1PL. We took advantage of 
the activity of FALDH, the next enzyme in the SL meta-
bolic pathway (Fig. 1). The human FALDH (also known as 
ALDH3A2) has been cloned and recombinant enzyme 
has been isolated from E. coli by Lloyd et al. (46), so this 
presented an attractive candidate for the development 
of a coupled assay. A commercially available cDNA clone 
(Source BioScience, product code IRAUp969B0810D in 
plasmid pOTB7) was used to construct an expression clone 
of the full-length FALDH protein (isoform 1); however, in 
our hands, this initial construct was insoluble (data not 
shown). A sequence alignment between human FALDH 
and rat ALDH3A1, which lacks a hydrophobic C-terminal 
transmembrane (TM) region, guided the preparation 
of a second truncated clone (supplemental Fig. S5). This 
shorter variant expressed well in E. coli and we were able to 
isolate milligram quantities of recombinant His-tagged hu-
man FALDH (supplemental Fig. S6). By monitoring alde-
hyde substrate-dependent NADH formation at 340 nm, we 
established that the fully saturated substrates, hexadecanal 
and tetradecanal, and, most importantly, the unsaturated 
2E-HEX, were substrates for this recombinant FALDH 
(Fig. 4A). Using varying 2E-HEX substrate concentrations 
(0–260 M), the reaction was linear over the first 3 min and 
the limit of detection was determined to be 4 M 2E-HEX 
N termini (supplemental Fig. S2), with the pairwise align-
ment beginning at M47 of StS1PL. This aligns well with a 
conserved MDLEEG motif found in S1PL2021 and the 
other S1PL homologs in Burkholderia species and two clones 
were prepared; one that began at the conserved MDLEEG 
motif (named S1PL2021) and another that expressed an 
extended construct [named S1PL2021 (N-EXT)].
Purification and characterization of S1PL2021 and 
S1PL2021 N-EXT
Recombinant S1PL2021 was expressed in E. coli from 
plasmid pET-28a as a hexa-histidine (6His) C-terminal fu-
sion. A standard purification procedure using immobilized 
nickel affinity chromatography and size-exclusion chroma-
tography yielded milligram amounts of pure recombinant 
protein S1PL2021 that was predominantly dimeric in so-
lution (supplemental Fig. S3A, B). A similar strategy was 
used to prepare recombinant S1PL2025 (supplemental 
Fig. S3C, D). Analysis of S1PL2021 suggested that PLP was 
bound to the protein because the UV-vis spectrum displayed 
absorbances at 330 and 420 nm that were characteristic 
of PLP-dependent enzymes (supplemental Fig. S3E). A 
similar PLP binding spectrum was observed with S1PL2025 
(supplemental Fig. S3F). In contrast, the alternative con-
struct, S1PL2021 N-EXT, purified in an identical manner to 
the S1PL2021, but failed to display any PLP binding (supple-
mental Fig. S3G). These results confirmed that these trun-
cated versions of S1PL2021 and S1PL2025 bound PLP and 
these forms of the protein were used throughout the study.
Substrate and product binding to S1PL2021
When the substrate S1P (100 M) was added to the PLP-
bound form of S1PL2021 (15 M) and the resulting mix-
ture analyzed by UV-vis spectroscopy, the peak at 420 nm 
decreased along with an increase in the 330 nm region 
over a period of 30 min, suggesting that S1P binds to 
S1PL2021 (Fig. 2A). Addition of the product PE (10 mM) 
to the protein also showed changes in the UV-vis region 
(maxima at 320 nm) with an additional blue shift to 
395 nm, although this occurred at a much slower rate 
than for S1P (Fig. 2B). According to the putative S1PL 
mechanism proposed by Bourquin et al. (44), these spec-
troscopic changes are due to the formation of the PLP-S1P 
and PLP-PE external aldimine intermediates that are bound 
to S1PL (supplemental Fig. S4). We carried out similar UV-
vis analysis of the binding of S1P and PE to the S1PL2025 
enzyme (Fig. 2C, D). The changes in the UV-vis spectra were 
similar when we compared the incubation of S1PL2021 
and S1PL2025 with S1P. In contrast, when we compared 
the spectra from the incubations of the product PE with 
both enzymes, we did not observe the 420–395 nm shift in 
the S1PL2025 enzyme and the changes took longer to oc-
cur compared with the S1PL2021 enzyme. These combined 
data suggest that, despite having highly similar amino acid 
sequences (86%), the two S1PL isoforms display small dif-
ferences in their cofactor, substrate, and product binding 
that deserve further investigation. We also used UV-vis spec-
troscopy to show that S1PL2021 could also bind the non-
phosphorylated substrate, D-erythro sphingosine (Fig. 2E). 
 at N
ew
castle University, on M
arch 10, 2017
w
w
w
.jlr.org
D
ow
nloaded from
 
.html 
http://www.jlr.org/content/suppl/2016/10/26/jlr.M071258.DC1
Supplemental Material can be found at:
142 Journal of Lipid Research Volume 58, 2017
Fig. 2. UV-vis spectroscopy analysis of purified S1PL2021. A: The UV-vis spectrum of PLP-bound S1PL2021 changes upon incubation with 
100 M S1P substrate in a time-dependent manner. Over 30 min (scanning every 3 mins), a decrease in absorbance at 420 nm, coupled to 
an increase in the 330 nm region is observed. The structure of the PLP-S1P external aldimine substrate is shown. B: Addition of 10 mM PE 
to S1PL2021 results in changes to the PLP spectrum over a longer timeframe (3 h, scanning every 30 min). There is a shift of the 420 nm 
peak to 395 nm and a broader increase in the 320–380 nm region associated with the formation of PLP-PE external aldimine (structure 
shown). C: Addition of 100 M S1P to S1PL2025 leads to changes in the PLP UV-vis spectrum region similar to that observed with S1PL2021 
(30 min, with scans every 3 min). D: Addition of 10 mM PE to S1PL2025 results in changes to the PLP spectrum over a longer timeframe (3 h, 
scanning every 30 min). E: Addition of 300 M D-erythro sphingosine to S1PL2021 results in changes to the PLP spectrum (4 h, scanning 
every 30 min).
(supplemental Fig. S7A). We performed Michaelis-Menten 
analysis and determined the kinetic values for 2E-HEX 
with KM = 19.4 ± 3.2 M and kcat = 0.22 ± 0.01 s
1 recorded 
(Fig. 4B, Table 1). The active FALDH was then coupled to 
both S1PL2021 and S1PL2025 in the presence of S1P and 
NAD+ at 30°C to determine the kinetic constants of both 
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commercially available screens. Crystals with a monoclinic 
morphology were grown in 20% (v/v) PEG400 and 10% 
(v/v) 1-propanol. Diffraction data on cryocooled crystals 
were collected on a single crystal at Diamond Light Source 
(beamline I03) to a maximum resolution of 2.1 Å in space 
group P1 21 1. The structure of S1PL2021 was determined 
by molecular replacement using a monomer of the S. ther-
mophilum S1PL structure as the template (PDB code, 
3MAD). The final refined model contains a dimer of S1PL 
with the PLP cofactor present as an internal aldimine with 
residue K271 in each chain (Fig. 5A). There was no clear 
electron density present for residues before L10, between 
residues H430 and A455, and for the His6 tag after residue 
P472 at the C terminus; residues in these regions were 
omitted from the final model (Table 2, Fig. 5A).
The S1PL2021 structure conformed to the typical type I 
PLP-dependent fold seen in the group II decarboxylase 
subfamily (11, 44). The overall architecture of the protein 
closely matches homologous structures, with excellent 
overall alignment of S1PL2021 with published structures 
(supplemental Fig. S8A, supplemental Table S1). The struc-
ture has an N-terminal domain (residues 10-55), which is 
primarily involved in dimerization, a large cofactor-binding 
S1PL enzymes. The initial reaction rates were linear over a 
S1P concentration range of 0–175 M. Therefore, S1PL 
activity could be quantified in a continuous fashion (down 
to a S1P substrate concentration of 10 M) (supplemen-
tal Fig. S7B, C) and allowed the determination of the ki-
netic constants of both B. pseudomallei S1PLs. The values for 
each are as follows: S1PL2021 (KM = 48.2 ± 9.4 M and kcat = 
0.015 ± 0.003 s1) and S1PL2025 (KM = 50.2 ± 8.3 M and 
kcat = 0.008 ± 0.0005 s
1) (Fig. 4C, D; Table 1). Thus, this 
new assay offered a convenient way of measuring the activ-
ity of recombinant S1PL. Based on the S1PL sequence 
alignment, residue K271 of S1PL2021 is predicted to bind 
the essential PLP cofactor (supplemental Fig. S2). A 
S1PL2021 K271A mutant was prepared and, when used in 
the coupled assay, this variant was essentially inactive in 
comparison to the wild-type enzyme (Fig. 4E). We also used 
the assay to determine whether S1PL2021 used D-erythro 
sphingosine as a substrate and found that it displayed 8% 
activity compared with S1P (Fig. 4F).
Structural characterization of S1PL2021
To further characterize the B. pseudomallei S1PL en-
zymes, we subjected S1PL2021 to crystallization trials using 
Fig. 3. Analysis of S1PL2021 activity by the Berdyshev et al. (26) method. A: The reaction between 2E-HEX and semicarbazide leads to 
formation of the semicarbazone derivative (2E-HEX SC), which under ESI-MS gives an ion with a predicted value of m/z 296.3 Da ([M+H]+, 
C17H34N3O
+). B: ESI-MS analysis of the 2E-HEX positive control reaction showing an ion with m/z 296.3 Da corresponding to the 2E-HEX SC. 
C: Incubation of S1P in buffer followed by semicarbazide derivitization in the absence of enzyme. The ion with m/z 296.3 Da is absent, but 
an ion with m/z 380.4 Da corresponding to S1P is observed ([M+H]+, C18H38NO5P = 380.2 Da, predicted). D: The S1PL2021 enzymatic reac-
tion showing the formation of the 2E-HEX SC ion with m/z 296.3 Da confirming the activity of S1PL2021. E: The no substrate control lacking 
S1P and the 2E-HEX SC.
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through a hydrogen bond between D268 and the sidechain 
nitrogen that forms the Schiff base with PLP.
The dimer observed in the crystal structure of S1PL2021 is 
the native form of this protein (Fig. 5A), as the cofactor-
binding site and ligand-binding funnel is formed be-
tween the two monomers (supplemental Fig. S9A, B). The 
dimerization interface buries nearly 50% of the total surface 
area of each monomer with a total buried area of 6,430 Å2; 
the interface is stabilized by 52 hydrogen bonds and 32 salt 
bridges. The observation that S1PL2021 is unable to bind 
PLP when expressed in the full-length form, as annotated in 
the genome, is explained by the fact that any significant ex-
tension of the N terminus of the structure from that seen in 
the crystal structure would potentially occlude the substrate 
binding funnel and PLP binding site (supplemental Fig. 
S9A). The substrate-binding funnel of S1PL2021 is formed 
between the two monomers, with one monomer providing a 
primarily positively charged surface and the other a nega-
tively charged surface (supplemental Fig. S9B). The missing 
region of the protein that forms the C-terminal extension is 
likely to play a role in substrate recognition, given its position 
over the funnel and its inherent flexibility in this structure.
DISCUSSION
SLs and ceramides have been shown to be important 
players in various eukaryotic cell functions. The amino 
central domain (residues 56-320), a short C-terminal do-
main (residues 321-430), and a C-terminal extension (resi-
dues 431-471) (Fig. 5A). The latter domain is partially 
disordered, with the region between residues 431 and 455 
not visible in the experimental electron density; this region 
sits close to the cofactor and substrate-binding region and 
may change conformation on ligand binding.
The cofactor-binding site at the dimer interface shows 
excellent electron density for the PLP cofactor, which was 
found to bind to K271 via a Schiff base as an internal aldi-
mine (Fig. 5B). Coupled with the high conservation of ac-
tive site residues with other members of the S1PL family 
across bacteria, yeast, and human (supplemental Fig. S8B, 
supplemental Table S2), our structural data confirm the 
assignment of S1PL2021 as a member of the S1PL (EC 
number 4.1.2.27) and, given the high sequence identity of 
S1PL2025 (86%), suggest that this is also a S1PL family en-
zyme. The cluster of residues involved in PLP binding are 
highly conserved across the members of the S1PL family, 
with these residues adopting the same orientation in pub-
lished crystal structures (supplemental Fig. S8B). Analysis 
of the active site shows that the pyridine ring is held in 
place between C235 and H159 with -stacking interactions 
to the latter residue; the nitrogen of the pyridine group 
forms a hydrogen bond to D233 (Fig. 5B). The PLP phos-
phate group forms hydrogen bonds with the sidechain of 
H270 and the backbone nitrogens of G126, T127, and S313 
from the partner chain. The K271 chain is held in place 
Fig. 4. Kinetic analysis of FALDH and S1PL2021/
S1PL2025. A: Recombinant human FALDH (0.5 M) 
displays enzyme activity with aldehyde substrates, 2E-
HEX, hexadecanal, and tetradecanal. B: Michaelis-
Menten kinetic analysis of FALDH using 2E-HEX as a 
substrate (0–260 M). The KM for 2E-HEX = 19.4 ± 
3.2 M and kcat = 0.22 ± 0.01 s
1. C, D: Michaelis-Men-
ten kinetic analysis using the S1PL/FALDH coupled 
assays with S1P as substrate (6.0 M S1PL, 0.5 M 
FALDH). The KM and kcat values for S1P are: 48.2 ± 
9.4 M and 0.015 ± 0.003 s1 for (C) S1PL2021 and 
50.2 ± 8.3 M and 0.008 ± 0.0005 s1 for (D) S1PL2025. 
E: The S1PL2021 K271A mutant displays negligible 
activity when using the coupled assay. F: Use of the cou-
pled assay to allow comparison of the S1PL20121 lyase 
activity with S1P (100 M) and D-erythro sphingosine 
(300 M) substrates.
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the same time, there was a decrease in the absorbance at 
420 nm. Addition of the product PE to S1PL2021 led to the 
appearance of a peak at 320 nm and a decrease at 420 nm 
with a shift to 395 nm (Fig. 2B). We carried out the same 
substrate and product binding analyses with S1PL2025 
(Fig. 2C, D) and the general trend was similar; this was un-
surprising, as they are 86% identical. In contrast, in their 
studies with the S. thermophilum S1PL, Bourquin et al. (44) 
observed the transient appearance of two peaks (403 and 
420 nm), which they tentatively assigned as the PLP-S1P 
and PLP-PE external aldimines in the putative S1PL reac-
tion mechanism (intermediates 3 and 7 respectively in 
supplemental Fig. S4). These peaks appeared immediately 
upon S1P addition, and then reduced over 5 min until the 
spectrum resembled that of the starting PLP-bound holo-
form of the enzyme. Moreover, they noted that the yeast 
S1PL UV-vis spectrum did not show any changes upon S1P 
addition and they concluded that this enzyme was inactive. 
Our MS and FALDH coupled assay (described below) 
prove that both Burkholderia S1PL2021 and S1PL2025 are 
active. Given that the S1PLs did not regenerate the holo-
form spectrum, it suggests differences between the Burk-
holderia S1PLs and the S. thermophilum S1PL with which they 
share 40% sequence identity. Our results could indicate 
the slow release of products (PE or 2E-HEX) or the buildup 
of a hitherto uncharacterized intermediate.
The ability to measure S1PL activity using a convenient 
method would help to expand structural and mechanistic 
studies of the enzyme in all organisms. Since the first dis-
covery of S1PL activity in mammalian cells by Stoffel, Lekim, 
and Sticht (52), who used a 14C-labeled substrate, a num-
ber of S1PL assays have been developed that use radioac-
tive, fluorescent, and fluorogenic substrates and substrate 
analogs. One of the earliest methods used incorporation of 
3H labels into the S1P substrate and TLC and liquid scintil-
lation counting analysis of the products. This was applied 
to the study of the S1PL enzyme in rat liver and values of 
KM = 9 M and Vmax = 0.082 pmol/min/g were deter-
mined (22). Bandhuvula, Fyrst, and Saba (23) synthesized 
a fluorescent NBD-labeled S1P homolog (S1P-C18NBD) 
that was used to analyze the human S1PL in HEK293 cells 
and gave values of KM = 14.6 M and Vmax = 3.4 × 10
4 
pmol/min/g. These authors then prepared a more stable 
fluorescent S1P-C14 BODIPY analog that was used to ana-
lyze the human enzyme again in HEK293 cells that gave 
values KM = 35 M and Vmax = 5.1 × 10
4 pmol/min/g, in 
good agreement with the previous study (24). An alterna-
tive clever strategy retained the phosphorylated amino al-
cohol structure of the natural S1P substrate and combined 
it with an ether-linked coumarin-based reporter to gener-
ate a substrate that, upon S1PL-catalyzed cleavage, breaks 
alcohol core structure of all SLs is built from L-serine and 
a long chain fatty acid and further elaborated by a series of 
enzymes that increase their complexity by phosphoryla-
tion, oxidation, and acylation (1). Cells maintain a balance 
of SLs and ceramides via highly regulated synthetic and 
metabolic pathways whose control mechanisms are still not 
fully understood. Perturbation of this balance has now 
been linked to a number of diseases such as cancer, athero-
sclerosis, autoimmunity, and infection (5, 6). A key regula-
tory mechanism involves the breakdown of the potent 
signaling molecule, S1P, by S1PL and S. cerevisiae has been 
a useful model organism where the pathways for de novo 
biosynthesis, recycling, and degradation of SLs have been 
delineated (47). Indeed, the first S1PL gene (dpl1) was char-
acterized in S. cerevisiae by Saba et al. (9) and they showed 
that a Dpl1 mutant strain was not only highly sensitive to 
exogenous sphingosine, but also accumulated intracellular 
S1P upon exposure to sphingosine. In contrast to higher 
order organisms, relatively few studies have been carried 
out to investigate the role of SL biosynthesis and metabo-
lism in bacterial species. Of these, it is interesting to note 
that microbes from the human microbiome, P. gingivalis 
from the oral cavity and the gut commensal B. fragilis, make 
SLs with unusual structural features (14–16). Their roles in 
bacterial metabolism, as well as their interaction within the 
host environment, are currently under investigation (48).
Burkholderia are a group of interesting bacterial species 
that can cause life-threatening infections and have a repu-
tation as being highly resistant to antibiotics (49–51) They 
appear to lack the ability to synthesize de novo SLs because 
analysis of their genomes suggests that the biosynthetic 
genes are absent. We were therefore interested to discover 
that B. pseudomallei K96243 encodes two highly homolo-
gous ORFs that display moderate (40%) sequence identity 
to the S. thermophilum S1PL query sequence (supplemental 
Figs. S1, S2). The two ORFs, BPSS2021 and BPSS2025 (an-
notated as decarboxylases in the genome), also display 
86% sequence identity to each other. Because a more de-
tailed sequence and structural analysis revealed that both 
ORFs contained conserved residues important for binding 
the PLP cofactor and enzyme catalysis, we hypothesized 
that these genes encode S1PLs. Therefore, we cloned, ex-
pressed, and purified recombinant forms of both S1PLs 
and UV-vis analysis showed that they bound the PLP cofac-
tor (supplemental Fig. S3). Monitoring the changes in the 
UV-vis spectrum of PLP-dependent enzymes can be a use-
ful tool to study how substrates, products, and inhibitors 
interact with these enzymes. The PLP binding region of 
holo-S1PL2021 showed changes upon addition of 100 M 
S1P with an initial sharp rise in the 330 nm region, fol-
lowed by a slower increase at this wavelength (Fig. 2A). At 
TABLE 1. Michaelis-Menten kinetic data for recombinant human FALDH using 2E-HEX as substrate and the B. 
pseudomallei S1PL2021 and S1PL2025 enzymes using S1P as a substrate
FALDH (2E-HEX as Substrate) S1PL2021 (S1P as Substrate) S1PL2025 (S1P as Substrate)
Vmax (nmol/min/mg) 314.9 ± 13.9 17.5 ± 1.3 8.2 ± 1.8
KM (M) 19.4 ± 3.2 48.2 ± 9.4 50.19 ± 8.3
kcat (s
1) 0.22 ± 0.01 0.015 ± 0.003 0.008 ± 0.0005
kcat/KM (M
1s1) 1.13 × 104 3.2 × 102 1.5 × 102
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GC-electron ionization MS method used pentafluoroben-
zoyloxime derivitization of the 2E-HEX to analyze the S1PL 
in mouse embryonic fibroblasts (KM = 6 M, Vmax = 0.374 
pmol/min/g) (27). Novartis has recently identified the 
human S1PL as an attractive target for the development of 
therapeutics and developed a high throughput MS-based 
method to screen for novel inhibitors (11). By using nico-
tinylhydrazide (Isoniazid) modification of the 2E-HEX, 
they obtained the first data on purified recombinant hu-
man S1PL (KM = 5.2 ± 0.9 M). Most recently, Suh et al. 
(53) developed a stable isotope dilution method using an 
internal D-labeled standard to also determine the values 
down by -elimination to a highly fluorescent umbellifer-
one product. Although highly sensitive, this nonnative 
substrate displays a high KM (152 M) for the S1PL in 
mouse embryonic fibroblasts and the fluorescence was sig-
nificantly reduced in the presence of Triton X-100 that is 
used to solubilize the S1P (25). MS-based techniques have 
also been developed that involve the derivitization of the 
2E-HEX aldehyde product with reagents (usually hydra-
zides) that improve ionization efficiency. The first MS-
based method was developed by Berdyshev et al. (26) to 
characterize the S1PL activity in mouse liver microsomal 
extracts (KM = 5.7 M, Vmax = 0.171 pmol/min/g). A similar 
Fig. 5. Structure of S1PL2021. A: Orthogonal views of the secondary structure of the S1PL2021 homodimer (PDB code, 5K1R). The two 
chains present in the asymmetric unit are shown as cartoon representations in green and red. The PLP cofactor bound as an internal aldi-
mine to K271 is shown as sticks (LLP271). The region of the protein between residues 430 and 455 that was absent from the experimental 
electron density is modeled based on homologous structures; the dashed lines represent loops and circle represents an  helix. B: Stereo 
view of the PLP-binding site of S1PL2021. Residues within 4 Å of the PLP cofactor are shown as sticks. Water molecules in this site are shown 
as crosses. The experimental 2mFo-DFc electron density is shown contoured at 1.5  around the internal aldimine formed between the PLP 
and K271 (LLP271). The PLP binding site is at the dimer interface and residues from each monomer are colored green and red.
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36 residues that contained a predicted potential TM do-
main (supplemental Fig. S5). Of note, Lloyd et al. (46) did 
not prepare 2E-HEX, but did show that the FALDH used 
the commercially available unsaturated cis-11-hexadecenal 
as a substrate. We found that our truncated recombinant 
FALDH was not only active with the saturated C14 and C16 
fatty aldehydes, but, more importantly, also used the syn-
thetic 2E-HEX as a substrate and we determined kinetic 
values (KM = 19.4 ± 3.2 M and kcat = 0.22 ± 0.01 s
1) that 
suggested that it would make a suitable coupling partner 
for the determination of S1PL activity (Fig. 4A, B).
During our work, a detailed X-ray structure and mecha-
nistic study of the human FALDH was published with a view 
to understanding the substrate specificity of the enzyme 
and the impact of mutations that cause Sjogren-Larsson 
syndrome (54). In this report, the FALDH construct con-
tained an N-terminal streptavidin affinity tag and, in com-
parison to our truncation, only removed the C-terminal 22 
amino acids, the minimum based on the proposed TM re-
gion. This construct was catalytically active with C8, C12, 
and C16 saturated aldehyde substrates in the presence of 
0.1% Triton X-100, but they noted that removal of a 40 
amino acid section resulted in a drastic reduction in activity 
with the longer acyl-chain length substrates. The X-ray 
structure of the FALDH (PDB code, 4QGK; 2.1 Å resolu-
tion) revealed that, as well as being involved in the TM 
interaction, the C-terminal domain also contained a gate-
keeper helix that is proposed to be involved in substrate 
specificity (supplemental Fig. 5B). This structure allowed 
us to rationalize how our truncation of the C-terminal hy-
drophobic element increased the solubility of our FALDH 
construct while retaining enough of the helix to main-
tain good activity toward long acyl chain substrates, cru-
cially including 2E-HEX (supplemental Fig. S5A, B). We 
combined our FALDH with the purified Burkholderia 
S1PL2021 and S1PL2025 enzymes in the presence of PLP, 
NAD+, and S1P solubilized in Triton X-100. We observed 
that the assay was linear over a practical substrate range 
(0–175 M) and determined kinetic values for S1PL2021 
(KM = 48.2 ± 9.4 M and kcat = 0.015 ± 0.003 s
1) and 
S1PL2025 (KM = 50.2 ± 8.3 M and kcat = 0.008 ± 0.0005 s
1) 
(Fig. 4C, D; Table 1). Because both isoforms display such 
high sequence identity, it is not surprising that they display 
similar KM values for S1P; however, we noted that the 
S1PL2025 was 50% slower than the S1PL2021 isoform. Al-
though we used this assay to only study the Burkholderia 
S1PLs, we think that this convenient FALDH-coupled 
method will be of use to those working with S1PLs from 
other organisms (e.g., yeast and human). It will be interest-
ing to determine whether it can also be applied not only to 
purified recombinant enzymes and HTP S1PL inhibitor 
screens, but also to whole cell lysates.
To explore the structures of these novel Burkholderia 
S1PLs, we used our optimized expression system for 
S1PL2021 to prepare crystals that diffracted to 2.1 Å. Using 
the S. thermophilum S1PL structure (PDB code, 3MAD) as a 
template for molecular replacement, the structure refined 
well and the enzyme displayed the canonical type I fold of 
the PLP superfamily of enzymes (Fig. 5A, supplemental 
for recombinant human S1PL in good agreement with the 
value determined by Novartis (KM = 4.67 M, Vmax = 2.6 
pmol/min/g).
We decided to use an MS-based method to confirm that 
the recombinant B. pseudomallei S1PL2021 isoform cata-
lyzed the degradation of S1P to 2E-HEX (Fig. 3). Because 
this end-point method involves a number of liquid han-
dling steps (derivitization, organic extraction) and requires 
an internal standard, we sought to develop a convenient 
continuous spectroscopic assay that could be used for S1PL 
analysis. Our choice of coupling enzyme was informed by 
our knowledge of the SL degradative pathway (Fig. 1). In 
mammals, the 2E-HEX aldehyde product of the S1PL en-
zyme is oxidized to the acid by a FALDH (also known as 
ALDH3A2; UniProt code, P51648) in an NAD+-dependent 
manner that can be monitored at 340 nm. Human FALDH 
has been the subject of various studies because it has 
been linked to the SL-metabolic disease, Sjögren-Larsson 
syndrome (8). Previously, recombinant full-length human 
FALDH had been isolated by Lloyd et al. (46), who showed 
that extraction of the enzyme from E. coli required the use 
of the anionic detergent, N-lauroylsarcosine. This enzyme 
displays broad substrate specificity and can use saturated 
fatty aldehydes of varying chain lengths (from C5 to C18) 
with KM values in the low micromolar range (4–35 M) and 
kcat values of 1 s
1 that would deem it suitable as a cou-
pling enzyme. We prepared recombinant N-terminally His-
tagged human FALDH by relatively straightforward soluble 
expression in E. coli, once we had removed the C-terminal 
TABLE 2. S1PL2021 X-ray crystallographic data collection and 
refinement statistics
Wavelength 0.976
Resolution range 43.27–2.104 (2.179–2.104)
Space group P 1 21 1
Unit cell 59.6 126.776 59.725 90 97.508 90
Total reflections 280,513 (25,538)
Unique reflections 50,729 (4,971)
Multiplicity 5.5 (5.1)
Completeness (%) 1.00 (0.98)
Mean I/sigma (I) 8.57 (1.87)
Wilson B-factor 32.55
R-merge 0.1336 (0.6925)
R-meas 0.1475 (0.7717)
CC1/2 0.994 (0.671)
CC* 0.999 (0.896)
Reflections used in refinement 50,714 (4,970)
Reflections used for R-free 2,637 (273)
R-work 0.1688 (0.2445)
R-free 0.2268 (0.3101)
CC (work) 0.947 (0.834)
CC (free) 0.932 (0.743)
Number of nonhydrogen atoms 7,190
Macromolecules 6,890
Protein residues 879
RMS (bonds) 0.013
RMS (angles) 1.22
Ramachandran favored (%) 97
Ramachandran allowed (%) 2.9
Ramachandran outliers (%) 0
Rotamer outliers (%) 1.8
Clashscore 3.26
Average B-factor 39.12
Macromolecules 39.17
Solvent 37.96
Values in parentheses are from the last resolution shell.  at N
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the surface that leads down into the active site (supplemen-
tal Fig. S9). It is interesting that one of the differences be-
tween the two enzymes is at position 401; this is a histidine 
in S1PL2021 and a glutamine in S1P2025. This change 
could contribute to the 50% difference in activity between 
the two isoforms. In the future, swapping the histidine at 
position 401 for glutamine (and vice versa) between the 
two forms, as well as mutating other potential residues, 
should identify those involved in substrate binding and ca-
talysis. Our continuous S1P assay will be useful for screen-
ing the activity of these and any other mutants.
Because human S1PL has recently been identified as an 
attractive target for drug discovery, both Novartis and Ab-
bVie have undertaken medicinal chemistry programs to 
identify potent inhibitors (11, 57). The determination of 
the structures of human S1PL and of the “humanized” 
S. thermophilum S1PL in complex with various inhibitors 
(PDB codes: 4Q6R, 5EUE, and 5EUD, respectively) have 
highlighted how these molecules block the substrate-
binding funnel. It will also be interesting to test these and 
other S1PL inhibitors against various bacterial S1PLs with a 
view to screen them for antibacterial activity.
To our knowledge, this is the first time that two highly-
related S1PLs have been identified in the same organism. 
At present, this phenomenon appears to be exclusive to 
species within the Burkholderia genus. The Burkholderia ge-
nus encompasses a remarkably diverse and versatile group 
of bacteria, including environmentally-beneficial species as 
well as pathogens of animals, humans, and plants. It is no-
table that our search of available genomes identified that 
Burkholderia-encoded S1PLs are restricted to B. pseudomallei 
and B. thailandensis, both of which are facultative intracel-
lular species. This is consistent with the bacterial S1PLs 
contributing to pathogenesis during infection of host cells, 
as has recently been described for Legionella-encoded S1PL 
(18). The ability to invade, survive, and replicate within 
host cells is central to the pathogenesis of B. pseudomallei 
(58) and, while B. thailandensis is a highly attenuated rela-
tive to B. pseudomallei, it displays a similar intracellular phe-
notype (59) and, as such, is a valuable model organism for 
studying the intracellular lifestyle of B. pseudomallei. SLs 
have been shown to be key players in cell homeostasis dur-
ing stress, such as that caused by bacterial infection (60). 
They mediate cross-talk between apoptosis and autophagy, 
the two major mechanisms of controlled cell death (61). 
Recently, studies on L. pneumophila, the causative agent of 
Legionnaires’ disease, have sought to understand the role 
that the L. pneumophila S1PL plays in its ability to survive 
intracellularly (18). It was found that L. pneumophila S1PL 
activity alone prevented an increase in sphingosine levels 
in infected host cells and this led to an inhibition of au-
tophagy during macrophage infection. This work revealed 
the disruption of host SL biosynthesis as a novel mecha-
nism used by intracellular pathogens to inhibit autophagy.
Because Burkholderia appear to not produce SLs such 
as S1P, the identity of the “true” intracellular substrate(s) 
for these enzymes is the subject of conjecture. We have 
shown that S1PL2021 can also degrade sphingosine as well 
as S1P, and it will be interesting to study a comprehensive 
Fig. 8A) (55). Furthermore, it belongs to the group II de-
carboxylase subfamily, which is typical of S1PLs from other 
species. The monomer has a three domain architecture: a 
short N-terminal domain, a large central domain that binds 
the well-resolved PLP cofactor bound as an internal aldi-
mine/Schiff base to K271, and an extended C-terminal 
domain (Fig. 5A). As well as K271, comparison with other 
S1PLs identifies conserved residues involved in PLP bind-
ing: C235 and H159 bind to the pyridine ring, residues 
G126, T127, H270, and S313* (from the other subunit) co-
ordinate the phosphate group, and D233 is involved in salt 
bridge formation of the pyridine nitrogen (Fig. 5B, supple-
mental Table S2). An overlay of all the well-refined struc-
tures of S1PLs in the PDB with PLP and/or Pi bound shows 
that the S1PL2021 active site architecture is well-con-
served (supplemental Fig. S8B, supplemental Table S2). 
Given its role in anchoring the PLP cofactor, it is not sur-
prising that mutation of the conserved K271 drastically re-
duces S1PL activity to 2% when compared with wild-type 
(Fig. 4E). Both S1PLs showed activity with S1P as a sub-
strate, but we also wished to explore to determine whether 
the phosphate of S1P was required for activity. Because we 
had observed binding of D-erythro sphingosine to S1PL2021 
(Fig. 2E) by UV-vis spectroscopy, it was interesting to find 
that this isoform did catalyze breakdown of this nonphos-
phorylated SL (8% activity compared with S1P, Fig. 4F). 
Thus, it appears that the Burkholderia S1PLs display some 
substrate promiscuity and may be able to break down a 
range of both phosphorylated and nonphosphorylated 
SLs. In the future, it will be interesting to carry out a com-
prehensive substrate analysis with these enzymes and ex-
plore their specificity with respect to acyl chain length, C1 
head group, the oxidation state at C4-C5 (sphingosine/
sphinganine), and the C2-C3 stereochemistry (erythro/threo).
Although the crystal structures of S1PLs from S. ther-
mophilum, S. cerevisiae, humans, and L. pneumophila have 
been solved, the exact nature of substrate binding and en-
zyme catalysis are still unclear because the structure of a 
S1P-bound complex has not been determined (11, 18, 44). 
For example, in the putative mechanism, the active site 
base that deprotonates the S1P hydroxyl leading to the 
retro-aldol-like cleavage of the substrate has not been 
identified (supplemental Fig. S4). Bourquin et al. (44) de-
scribed a S. thermophilum S1PL:PLP-PE product complex as 
well as a S1PL:PLP internal aldimine with a phosphate ion 
bound and, together these structures, hinted at the resi-
dues involved in binding the phosphate of S1P. Despite 
screening numerous conditions, we were unable to trap 
the wild-type S1PL2021:PLP-S1P external aldimine complex 
because we assume the enzyme catalyzes the rapid break-
down of the S1P. We recently used mutagenesis of an active 
site lysine that allowed us to capture the PLP-dependent 
enzyme, serine palmitoyl transferase, bound to the inhibi-
tor, myriocin (56). We used a similar strategy to screen crys-
tals of the S1PL2021 K271A mutant for S1P binding, but 
this has so far failed to yield a structure (data not shown). 
To date, the exact residues involved in binding the S1P acyl 
chain are still not known, but an overlay of all available 
S1PLs suggests the presence of a hydrophobic funnel on 
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range of potential substrates with each S1PL isoform to de-
fine their specificity. Burkholderia would most likely encoun-
ter high concentrations of S1P only during infection of a 
mammalian host and this would require the S1PLs to be 
secreted. In a recent complementary study, we have discov-
ered that the two S1PL homologs present in B. thailandensis 
(BTH_II0309 and BTH_II0311; supplemental Fig. S1) are 
found in the extracellular supernatant in a pH-dependent 
manner (62). We are currently investigating whether both 
of these S1PLs form part of a higher order complex as pairs 
of homo- or heterodimers, but initial native gel electropho-
resis suggests the presence of larger complexes. We also 
found that when expressed alone, BTH_II0309 and BTH_
II0311 could each partially restore resistance to 10 M 
sphingosine treatment of a yeast Dpl1 mutant and full resis-
tance was displayed by cells expressing both S1PLs. Our 
future work will determine whether the B. pseudomallei 
S1PL2021 and S1PL2025 can also complement the yeast 
Dpl1 mutant and are secreted in a similar way to the 
B. thailandensis isoforms. We studied the functional roles of 
the Burkholderia S1PLs and found that they were required 
for virulence in a Galleria wax moth larvae model and sur-
vival in murine macrophages (62). Of particular relevance 
to the current study, we discovered that a B. pseudomallei 
S1PL2025 mutant displayed a much reduced virulence 
phenotype (80% survival) compared with the wild-type or-
ganism (100% mortality) using a murine infection model 
in BALB/c mice. We are currently constructing the B. pseu-
domallei S1PL2021 knockout and a double mutant to study 
their virulence phenotypes. In summary, our work has 
characterized two S1PL homologs in B. pseudomallei and, 
when combined with recent studies on the emerging roles 
of bacterial S1PLs in pathogenesis, suggests that these en-
zymes merit further study.
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